Literature DB >> 16540497

Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.

J P J J Hegmans1, A Hemmes, H Hammad, L Boon, H C Hoogsteden, B N Lambrecht.   

Abstract

Malignant mesothelioma is a cancer with dismal prognosis. The objective of the present study was to address the role of the immune system, tumour micro-environment and potential immunosuppression in mesothelioma. Expression profiles of 80 cytokines were determined in the supernatant of mesothelioma cell lines and the original patient's pleural effusion. Influx of immune effector cells was detected by immunohistochemistry. Angiogenin, vascular endothelial growth factor, transforming growth factor-beta, epithelial neutrophil-activating protein-78 and several other proteins involved in immune suppression, angiogenesis and plasma extravasation could be detected in both supernatant and pleural effusion. Surrounding stroma and/or infiltrating cells were the most likely source of hepatocyte growth factor, macrophage inflammatory protein (MIP)-1delta, MIP-3alpha, neutrophil-activating peptide-2, and pulmonary and activation-regulated chemokine that can cause leukocyte infiltration and activation. There was a massive influx of CD4+ and CD8+ T-lymphocytes and macrophages, but not of dendritic cells, in human mesothelioma biopsies. It was further demonstrated that human mesothelioma tissue contained significant amounts of Foxp3+CD4+CD25+ regulatory T-cells. When these CD25+ regulatory T-cells were depleted in an in vivo mouse model, survival increased. Mesothelioma is infiltrated by immune effector cells but also contains cytokines and regulatory T-cells that suppress an efficient immune response. Immunotherapy of mesothelioma might be more effective when combined with drugs that eliminate or control regulatory T-cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540497     DOI: 10.1183/09031936.06.00135305

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  53 in total

1.  A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas.

Authors:  Sherrill L Macura; Jedd M Hillegass; Jeremy L Steinbacher; Maximilian B MacPherson; Arti Shukla; Stacie L Beuschel; Timothy N Perkins; Kelly J Butnor; Melissa J Lathrop; Mutlay Sayan; Khan Hekmatyar; Douglas J Taatjes; Risto A Kauppinen; Christopher C Landry; Brooke T Mossman
Journal:  J Histochem Cytochem       Date:  2012-06-21       Impact factor: 2.479

Review 2.  The Role of Regulatory T Cells in Mesothelioma.

Authors:  Demelza J Ireland; Haydn T Kissick; Manfred W Beilharz
Journal:  Cancer Microenviron       Date:  2012-02-01

Review 3.  Novel targeted therapies and vaccination strategies for mesothelioma.

Authors:  Mamta Bagia; Anna K Nowak
Journal:  Curr Treat Options Oncol       Date:  2011-06

Review 4.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

5.  Inflammation in malignant mesothelioma - friend or foe?

Authors:  Anthony Linton; Nico van Zandwijk; Glen Reid; Stephen Clarke; Christopher Cao; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

6.  The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.

Authors:  Hideki Ujiie; Kyuichi Kadota; Jun-Ichi Nitadori; Joachim G Aerts; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Lee M Krug; Prasad S Adusumilli
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

Review 7.  Feasibility of immunotherapy for lymphangioleiomyomatosis.

Authors:  Michele Carbone
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

Review 8.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Authors:  Adam J Bograd; Kei Suzuki; Eva Vertes; Christos Colovos; Eduardo A Morales; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-09-13       Impact factor: 6.968

9.  Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.

Authors:  Chiara Riganti; Marcello Francesco Lingua; Iris Chiara Salaroglio; Chiara Falcomatà; Luisella Righi; Deborah Morena; Francesca Picca; Daniele Oddo; Joanna Kopecka; Monica Pradotto; Roberta Libener; Sara Orecchia; Paolo Bironzo; Valentina Comunanza; Federico Bussolino; Silvia Novello; Giorgio Vittorio Scagliotti; Federica Di Nicolantonio; Riccardo Taulli
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

10.  Combination immune checkpoint blockade as an effective therapy for mesothelioma.

Authors:  Vanessa S Fear; Caitlin Tilsed; Jonathan Chee; Catherine A Forbes; Thomas Casey; Jessica N Solin; Sally M Lansley; William Joost Lesterhuis; Ian M Dick; Anna K Nowak; Bruce W Robinson; Richard A Lake; Scott A Fisher
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.